The results of palliative intensive hypofractionated radiotherapy from patients having brain metastases with unknown primary tumour

Abstract

OBJECTIVES We retrospectively examined the results of hypofractionated radiotherapy from 24 patients having brain metastases with unknown primary. METHODS Radiotherapy was administered to 24 patients (20 males (83.4%), 4 females (16.6%), age range 24-75 years) as 10 Gy fraction doses with 10 days intervals for a total of 30 Gy tumour dose in 3 fractions. Antiedema treatment was given to all patients. Karnofsky performance status was 70 for one patient and below 70 for the rest of the patients. Multiple metastases were present in 79.2% of the patients, in 20.8% of the patients there was single lesion and histophatologic diagnosis was present only for this group. 50% of the patients had hemiplegia, 45.8% had hemiparesia, 4.2 % had quadriplegia and 6 patients (25%) had other additional pathologies. Treatment was started at the day of admission for 13 patients. RESULTS The total and partial reliefs in neurological symptoms were seen in 8.3% and 37.5% of patients, respectively. Median survival from diagnosis of brain lesions was 2.87 months. The six months, 1 and 2 years survival rates were 33.3%, 8.33%, and 8.33%, respectivel y. The prognosis of patients with brain metastases is poor and have similar survival rates from the other poor performance patients (KPS

Keywords

• Neoplasms, Unknown Primary,Brain Neoplasms,Neoplasm Metastasis,Radiotherapy,Dose Fractionation,Radiotherapy Dosage,Retrospective Studies,Survival Analysis

Beyin metastazıyla başvuran primeri bilinmeyen kanserli hastalarda palyatif entansif hipofraksiyone tüm beyin radyoterapisi sonuçları

Abstract

AMAÇ Bu çalışmada beyin metastazı ile tanı konulmuş ve primeri bilinmeyen 24 hastaya uygulanan palyatif amaçlı hipofraksiyone radyoterapi sonuçları retrospektif olarak incelendi. GEREÇ VE YÖNTEM Yirmi dört hastaya (20 erkek (%83.4), 4 kadın (%16.6); ort. yaş 61; dağılım 24-75 yıl) radyoterapi, 10 Gy fraksiyon dozlarında, 10 gün arayla; 3 fraksiyonda 30 Gy tümör dozu verilecek şekilde uygulandı. Tüm hastalara antiödem tedavi verildi. Bir hastada Karnofsky Performans Statüsü 70, diğer hastalarda 70'in altında idi. Hastaların %79.2'sinde multipl metastaz vardı; %20.8'inde tek lezyon mevcuttu ve yalnızca bu hastaların histopatolojik tanısı vardı. Hastaların %50'sinde hemipleji, %45.8'inde hemiparezi ve %4.2'sinde quadripleji ile 6 hastada (%25) bunlara ek patolojiler vardı. Tedaviye 13 hastada başvuruda bulundukları gün başlandı. BULGULAR Radyoterapi sonrası değerlendirmede hastaların %8.3'ünde nörolojik semptomlarda tam düzelme, %37.5'inde parsiyel düzelme, toplamda %45.8'inde nörolojik semptomlarda iyileşme görüldü. Sağkalım oranları ort. 2.87 ay olup altı aylık sağkalım %33.3, bir ve iki yıllık sağkalım %8.33 idi. Sonuçlarımız kötü performanslı hastalarda uygulanan diğer radyoterapi şemalarıyla benzer oldu (KPS < 70). SONUÇ Kötü performanslı, sağkalım beklentisi düşük olan hastalara kısa süreli tedaviler önerilebilir

Keywords

• Beyin neoplazisi/radyoterapi, doz fraksiyonu, beyin metastazı/prognoz/sağkalım analizi/sağkalım oranları

References

1. 1. Nussbaum ES, Djalilian HR, Cho KH, Hall WA. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 1996;78(8):1781-8.
2. 2. Wen PY, Loeffler JS. Management of brain metastases. Oncology (Williston Park) 1999;13(7):941-54, 957-61.
3. 3. O'Neill BP, Iturria NJ, Link MJ, Pollock BE, Ballman KV, O'Fallon JR. A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int J Radiat Oncol Biol Phys 2003;55(5):1169-76.
4. 4. van de Pol M, van Aalst VC, Wilmink JT, Twijnstra A. Brain metastases from an unknown primary tumour: which diagnostic procedures are indicated? J Neurol Neurosurg Psychiatry 1996;61(3):321-3.
5. 5. Merchut MP. Brain metastases from undiagnosed systemic neoplasms. Arch Intern Med 1989;149(5):1076- 80.
6. 6. Markesbery WR, Brooks WH, Gupta GD, Young AB. Treatment for patients with cerebral metastases. Arch Neurol 1978;35(11):754-6.
7. 7. Ruderman NB, Hall TC. Use of glucocorticoids in the palliative treatment of metastatic brain tumors. Cancer 1965;18:298-306.
8. 8. Tsao MN, Lloyd NS, Wong RK, Rakovitch E, Chow E, Laperriere N; Supportive Care Guidelines Group of Cancer Care Ontario's Program in Evidence-based Care. Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. Cancer Treat Rev 2005;31(4):256-73.

9. 9. van den Bent MJ. The diagnosis and management of brain metastases. Curr Opin Neurol 2001;14(6):717-23.
10. 10. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis ( R PA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37(4):745- 51.
11. 11. Agboola O, Benoit B, Cross P, Da Silva V, Esche B, Lesiuk H, et al. Prognostic factors derived from recursive partition analysis (RPA) of Radiation Therapy Oncology Group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases. Int J Radiat Oncol Biol Phys 1998;42(1):155-9.
12. 12.Renschler MF, Mehta MP, Donald DM, Fondrie P, Phan SC, Whitten TG. Treatment intent for brain metastases: surveys of medical and radiation oncologists indicate that maintaining neurologic and neurocognitive function is more important than prolonging survival. Proc Am Soc Clin Oncol 2003;22:552, (abstr 2222).
13. 13. Herman MA, Tremont-Lukats I, Meyers CA, Trask DD, Froseth C, Renschler MF, et al. Neurocognitive and functional assessment of patients with brain metastases: a pilot study. Am J Clin Oncol 2003;26(3):273-9.
14. 14.Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1980;6(1):1-9.
15. 15.Borgelt B, Gelber R, Larson M, Hendrickson F, Griffin T, Roth R. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1981;7(12):1633-8.
16. 16. Priestman TJ, Dunn J, Brada M, Rampling R, Baker PG. Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin Oncol (R Coll Radiol) 1996;8(5):308-15.